Brind.

Eli Lilly and Company announced agreements to acquire potential targets, filing reports with the SEC.

7 reports, 7 independent Updated Jul 17
Gone quiet Reached 6 outlets in its first 24 hours
Reports
7
Developments
5
Repetition
71%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 7 independent outlets

Eli Lilly and Company announced agreements to acquire potential targets, filing reports with the SEC.

Who's involved

What this event is mainly about

How it developed

Newest first. Tap a step to see who reported it.
  1. Eli Lilly and Company plans to acquire Merida Biosciences for up to $2.8 billion in cash.Sub-event
  2. Eli Lilly announced a partnership for a digital patient care solution with Senderra, though market dynamics caused stock issues.Sub-event
  3. Eli Lilly acquired Scorpion Therapeutics from Axel Hoos, who previously served as SVP at GSK.Sub-event
  4. Eli Lilly is pursuing acquisitions of potential targets and filing related reports with the SEC.1 source
  5. Eli Lilly and Company is actively acquiring three vaccine developers to diversify its pipeline, with the President also involved in investor relations.1 source

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • theepochtimes.com
  • dailypolitical.com
  • powderbulksolids.com
  • tickerreport.com
  • prnewswire.com
  • Motley FoolDoes This $856 Million Investment Make Eli Lilly Stock a Buy? Eli Lilly is investing money to help a smaller biotech develop a new class of small-molecule drugs. This move is another in a long list o
  • PR NewswireLilly and Verve announce expiration of Verve tender offer INDIANAPOLIS, July 24, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Verve Therapeutics, Inc. (NASDAQ: VERV) today announced tha